The trademark application NOVAVITA THERA was filed by Cytotheryx, Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on September 21, 2021, and it was registered by office on December 29, 2021 without any oppositions.
The application was filed in English (French was selected as the second language).
Goods And Services
The mark was filed in class 5 with following description of goods:
Gene therapies, namely, in vivo and ex vivo vector treatments
Lentiviral vector therapies
Gene therapies for the treatment of rare diseases
Gene therapies for hereditary tyrosinemia type 1
Gene therapies for orphan disease
Therapies for inborn errors of hepatic metabolism
All of the aforesaid being pharmaceuticals, medical and veterinary preparations.